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1 Co-ﬁrst authors.a b s t r a c t
In this study, we identiﬁed p53 as a novel TCTP-interacting protein using TCTP as bait. Also, we
determined the critical binding sites between TCTP and p53. To elucidate the functional conse-
quence of the interaction, we developed the overexpression and inhibition system of TCTP and
p53 expression. Overexpression of TCTP in lung carcinoma cells reversed p53 mediated apoptosis
and inhibition of TCTP expression by small interfering RNA increased apoptosis of lung carcinoma
cells. Moreover, it was observed that TCTP overexpression promotes degradation of p53. These
results clearly indicate that the interaction between TCTP and p53 prevents apoptosis by destabiliz-
ing p53. Thus, TCTP acts as a negative regulator of apoptosis in lung cancer.
Structured summary:
MINT-8057107, MINT-8057116: p53 (uniprotkb:P04637) physically interacts (MI:0915) with TCTP (uni-
protkb:P13693) by anti bait coimmunoprecipitation (MI:0006)
MINT-8057141: TCTP (uniprotkb:P13693) physically interacts (MI:0915) with p53 (uniprotkb:P04637) by
two hybrid pooling approach (MI:0398)
MINT-8057126: p53 (uniprotkb:P04637) physically interacts (MI:0915) with TCTP (uniprotkb:P13693) by
anti tag coimmunoprecipitation (MI:0007)
MINT-8057160: TCTP (uniprotkb:P13693) physically interacts (MI:0915) with p53 (uniprotkb:P04637) by
two hybrid (MI:0018)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Translationally controlled tumor protein (TCTP)/histamine
releasing factor (HRF), a 172 amino acid anti-apoptotic polypep-
tide, which is also a highly conserved hydrophilic protein [1], plays
a pivotal role in the development of different organisms [2]. TCTP is
a housekeeping gene abundantly expressed in many tissues and
cell types [3]. It is present both extra- and intracellular which
has been implicated in many cellular functions that are related to
cell growth, apoptosis regulation [4,5], and even the allergic re-
sponse [6]. TCTP also interacts with many cellular proteins, whichchemical Societies. Published by E
le; HRF, histamine releasing
yl-2H-tetrazolium bromide;
small interfering RNA; TCTP,
inal deoxynucleotidyl trans-include tubulin [4], translation elongation factors eEF1A and its
guanine nucleotide exchange factor eEF1B-b [7], Mcl-1 [1], TSAP6
[8], Na, K-ATPase [9], and Bcl-XL [10]. On the other hand, anti-
apoptotic activity has been reported for TCTP, which may be re-
lated to its interaction with Mcl-1 and/or Bcl-XL [1,11]. A recent
study demonstrated that overexpression of TCTP can prevent stress
induced mammalian cell apoptosis. Reversely, inhibition of TCTP in
a malignant human carcinoma cells increased apoptosis [3]. Thus,
TCTP may be involved in cell survival as a negative regulator of
apoptosis. However, the exact mechanisms of TCTP on physiologi-
cal functions regarding anti-apoptosis mediation are largely un-
known. p53 tumor suppression protein is encoded by the TP53
gene. p53 has a key role in mediating cellular response to various
stress signals, mainly by inducing or repressing a number of pro-
teins that are involved in cell cycle progression, apoptosis, DNA re-
pair, cellular senescence, chronic inﬂammation, and cellular
senescence [12–15]. As shown in some cancers, the interaction of
p53 with viral and cellular proteins leads to the inactivation of
p53 functions [16,17]. The activity of p53 is regulated at low levels
primarily due to the action of mouse or human double minute-2lsevier B.V. All rights reserved.
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major regulator of p53 protein, p53 functions are controlled in two
different ways: via the regulation of p53 transcriptional activity
and the intracellular p53 level [18,19].
By using yeast two-hybrid screening to address the apoptosis
regulatory mechanism related to TCTP proteins, we identiﬁed
p53 as a novel TCTP-interacting protein. p53 is a tumor suppressor
protein and a omnifunctional transcription regulator that plays an
essential role in cellular responses to various stress signals. p53
speciﬁcally interacted with TCTP both in vitro and in vivo. Tran-
sient transfection analyses demonstrated that overexpression of
TCTP blocks p53 mediated apoptotic activity by inducing the deg-
radation of p53. These results therefore support that a dynamic
equilibrium between pools of p53 and TCTP regulating apoptotic
homeostasis.2. Materials and methods
2.1. Screening of binding protein partner and quantitation of
interaction
For bait construction with human TCTP, cDNA encoding
full-length human TCTP was subcloned into the EcoRI and XhoI
restriction sites of the pGilda cloning vector. The resulting plasmid
pGilda-TCTP was introduced into yeast strain EGY48 by a modiﬁed
lithium acetate method [20]. The activity of the interaction
between TCTP and p53 was conﬁrmed by measuring the relative
expression level of b-galactosidase. The b-galactosidase assay
was determined according to the previously described method
[20] with slight modiﬁcation.
2.2. Cell culture and antibodies
Human lung carcinoma cells (A549) were cultured in a DMEM,
and were supplemented with 10% heat-inactivated FBS and antibi-
otics at 37 C in a humidiﬁed 5% CO2 incubator (Life Technologies,
Gaithersburg, MD). The following antibodies were used in this
study: anti-TCTP antibody (Oncogene, San Diego, CA), anti-p53
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-GFP (Santa Cruz),
anti-caspase 3 (Santa Cruz), anti-Bcl-2 (Santa Cruz), anti-BAX
(Santa Cruz), anti-tubulin (Santa Cruz) and anti-b-actin (Sigma,
St. Louis, MO).
2.3. Co-immunoprecipitation
cDNA encoding human p53 was cloned into pEGFP (Clontech)
and digested with BglII and EcoRI (pEGFP-p53). The human TCTP
cDNA was ligated into pcDNA4/HisMax (Invitrogen Life Technolo-
gies, Carlsbad, CA) using EcoRI and XhoI (pcDNA4/HisMax-TCTP).
For co-immunoprecipitation, A549 cells were co-transfected with
cDNA constructs of pEGFP-p53 and pcDNA4/HisMax-TCTP using
Fugene 6 Reagent (Roche, Mannheim, Germany) according to the
manufacturer’s protocol. Lysates were then incubated with anti-
GFP antibody (Santa Cruz) and precipitated with protein A-agarose
(Amersham). The precipitated proteins were resolved by SDS gel
electrophoresis, transferred onto Immobilon P membrane
(Millipore, Billerica, MA), and immunoblotted with anti-His anti-
body (Santa Cruz) or goat anti-TCTP antibody (Oncogene) using
the ECL system (Amersham).
2.4. Small interfering RNA (siRNA) construction
The small interfering RNA (siRNA) oligonucleotide sequence
targeting TCTP (50-AAGGTACCGAAAGCACAGT-30) corresponded to
nucleotides 179–197 in the human sequence. siRNA was synthe-sized by using an siRNA construction kit (Ambion, Austin, TX).
A549 cells were transfected with p53-speciﬁc siRNA SmartPool du-
plexes (Dharmacon, Lafayette, CO) at a ﬁnal concentration of
100 nM. Transfections were performed using Fugene 6 Reagent
(Roche) according to the manufacturer’s protocol.
2.5. Determination of p53 protein stability
A549 cells were transfected with mock (an expression vector
only), TCTP siRNAs, or co-transfected with p53 and the indicated
pEGFP-TCTP cDNA mutant. Three days after transfection, the cells
were treated with cycloheximide (Sigma) at a ﬁnal concentration
30 lg/ml. The cell lysates were subsequently harvested at sequen-
tial time points after treated, resolved through SDS gel electropho-
resis, transferred onto Immobilon P membranes (Millipore), and
immunoblotted with anti-p53 antibody.3. Results
3.1. Identiﬁcation of p53 as a TCTP-interacting protein
As an initial step to elucidate the regulation mechanism of TCTP,
we screened a human cDNA library using a yeast two-hybrid sys-
tem with TCTP as bait. Approximately 2.5  106 independent
transformants were pooled and spread again onto the selection
media (Ura, His, Trp, Leu) containing 2% (w/v) galactose in or-
der to induce cDNA expression. If a B42-tagged protein interacts
with the TCTP, the transcription of the LEU2 gene is activated, thus
allowing the host cells to grow on a leucine-deﬁcient synthetic
medium. Among the seven colonies obtained on the selection med-
ia, a total of ﬁve colonies showed galactose dependency. The plas-
mids were then isolated by the plasmid marker trp in the
Escherichia coli host, and the puriﬁed plasmids were sequenced. A
homology search in GenBank using the BLAST program revealed
that all plasmids encoded human p53 (GenBank accession number:
NM_000546). Human p53 cDNA has an open reading frame (ORF)
of 1182 bp and encoded 393 amino acids. All of the p53 encoded
plasmids identiﬁed in yeast two hybrid system contained a cDNA
with 100% identity to the V197-D393 of human p53 (two plasmids)
or G105-D393 of human p53 (three plasmids) including C-terminal
sequence of human p53 (Fig. 1A). To conﬁrm this result, we deter-
mined the binding activity between TCTP and p53 by measuring
the relative expression levels of b-galactosidase. As shown in
Fig. 1B, the b-galactosidase activity between TCTP and p53 was
fully observed, whereas very little b-galactosidase activity was ob-
served between TCTP and empty vector (vector only).
For co-immunoprecipitation, cDNA constructs of p53 (pEGFP-
p53) and TCTP (pcDNA4/HisMax-TCTP), or pEGFP-p53 and vector
only (pcDNA4/HisMax) were co-transfected into A549 cells
(human lung carcinoma cells). Subsequently, an immunoprecipita-
tion was performed using anti-GFP antibody with lysates from
both transfected cells. After immunoprecipitation, the precipitated
proteins were immunoblotted using anti-TCTP antibody or anti-
p53 antibody. As shown in Fig. 1C, pEGFP-p53 was co-immunopre-
cipitated with pcDNA4/HisMax-TCTP (lane 2 in upper panel),
whereas no interaction was observed between pcDNA4/HisMax
(vector only) and pEGFP-p53 (lane 1 in upper panel). An immuno-
blotting using anti-p53 antibody conﬁrmed that an equal amount
of p53 was precipitated in both samples (middle panel). Whole cell
lysates from both samples contained the equivalent proteins when
immunoblotted using anti-b-actin antibody (lower panel).
Next, we tested whether we can detect the interaction between
p53 and TCTP in endogenous level. Immunoprecipitation was sub-
sequently conducted using anti-p53 or anti-TCTP antibody with
whole cell lysates of A549 cells. After immunoprecipitation, the
Fig. 1. Interaction analysis of TCTP with p53 tumor suppressor protein. (A) The amino acid sequence of p53 is indicated using single letter abbreviations. An underlined amino
acid sequence means the translated p53 protein, isolated from yeast two-hybrid screening. (B) Positive interactions were revealed by observing cell growth over three days at
30 C on medium lacking leucine, and by the formation of blue colonies on medium containing X-gal. The values of b-galactosidase activity (unit) measured by adding
O-nitrophenyl b-D-galactopyranoside (ONPG) assays are indicated below the corresponding lanes. (C) Co-immunoprecipitation of TCTP with p53. Immunoprecipitation
was performed using an anti-GFP antibody with lysates from both transfected cells. After immunoprecipitation, precipitated proteins were immunoblotted using anti-
TCTP antibody and anti-p53 antibody. lane 1, pCDNA4/HisMax (vector only) and pEGFP-p53 transfectant; lane 2, pCDNA4/HisMax-TCTP and pEGFP-p53 transfectant.
(D) Co-immunoprecipitation between the endogenous p53 and TCTP display the interactions of the two proteins.
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anti-p53 antibody. As shown in Fig. 1D, TCTP was co-immunopre-
cipitated with p53 (upper left panel), whereas no interactions were
observed between isotype control (anti-IgG) and TCTP. Also, p53
was co-immunoprecipitated with TCTP (upper right panel),
whereas no interactions were observed between isotype control
(anti-IgG) and p53. Immunoblotting using anti-TCTP and p53 anti-
body veriﬁed that an equal quantity of both p53 and TCTP was
present in the whole cell lysates (middle panel). Also, the whole
cell lysates from both samples harbored the equivalent proteins
when immunoblotted using anti-b-actin antibody (lower panel).
These results clearly demonstrated that TCTP and p53 interact with
each other in the physiological context of a human cell.
3.2. Mapping of the interaction domain between TCTP and p53
To identify the p53 binding domain of TCTP, cDNA constructs
containing three p53 deletion mutants were designed as shown
in Fig. 2A (see detailed Materials and methods in Supplementary
data). These truncated domains were predicted to be predomi-
nantly a-helices. In the two-hybrid system, the full-length humanTCTP cDNA and either plasmid containing a full-length human
TCTP cDNA (left panel in Fig. 2A, full) or plasmids containing three
truncation mutant forms (left panel in Fig. 2A, Met1-Gly69,
Val70-Ala119, Glu120-Cys172) of cDNA were co-transformed into
EGY48 yeast cells. Cells containing full-length TCTP cDNA and also
one deletion mutant (Val70-Ala119) grew on the Ura, His, Trp and
Leu deﬁcient plates. Yeast cells transformed with the other
deletion mutants (Met1-Gly69 and Glu120-Cys172) failed to grow
(right panel in Fig. 2A). To conﬁrm this result, we determined the
binding activity of these constructs by measuring the relative
expression level of b-galactosidase. As shown in right panel in
Fig. 2A, b-galactosidase assay results conﬁrmed that either of these
mutants (Met1-Gly69 and Glu120-Cys172) cannot bind to p53. How-
ever, we cannot exclude that the p53 binding site of TCTP is located
near the junction of these mutants since b-galactosidase activity in
one deletion mutant (Val70-Ala119) is lower than full-length TCTP
(right panel in Fig. 2A).
Subsequently, cDNA constructs containing three p53 truncation
mutants were designed to localize the TCTP binding domain of p53
(left panel in Fig. 2B, full). In the two-hybrid system, the full-length
human TCTP cDNA and either plasmid containing a full-length
Fig. 2. Mapping of the critical interaction domain between TCTP and p53 using the yeast-two-hybrid system. (A) Left panel shows the schematic representation of cDNA
constructs for each TCTP deletion mutant and full-length TCTP fusion proteins. Right panel shows the result of protein–protein interaction determined in the yeast two-
hybrid system. The values of b-galactosidase activity in negative controls (vector only) of each construct were below 1.21 ± 0.37. (B) Left panel shows the schematic
representation of cDNA constructs for each p53 deletion mutant and full-length p53 fusion proteins. Right panel shows the result of protein-protein interaction determined in
the yeast two-hybrid system. The values of b-galactosidase activity in negative controls of each construct were below 1.55 ± 0.42. (C) Interaction between cDNA constructs for
a p53 (Lys101-Pro300) and three TCTP truncation (Met1-Gly69, Val70-Ala119, Glu120-Cys172) fusion proteins in the yeast two-hybrid system.
32 S.B. Rho et al. / FEBS Letters 585 (2011) 29–35human p53 (left panel in Fig. 2B, full) or three truncation mutant
forms (left panel in Fig. 2B, Met1-Gln100, Lys101-Pro300, Pro301-
Asp393) of cDNAs were co-transformed into EGY48 yeast cells
(see detailed Materials and methods in Supplementary data). Cells
containing full-length TCTP cDNA and also one deletion mutant
(Lys101-Pro300) grew on the Ura, His, Trp and Leu deﬁcient plates.
Yeast cells transformed with the other deletion mutants (Met1-
Gln100 and Pro301-Asp393) failed to grow (right panel in Fig. 2B).
We also quantitated the binding activity of these constructs by
measuring the relative expression level of b-galactosidase. Results
on b-galactosidase assay also indicated that the critical p53 region
for binding TCTP resided within Lys101-Pro300 including the DNA-
binding motif of p53 (right panel in Fig. 2B).
To conﬁrm these results, one deletion mutant of p53 (Lys101-
Pro300) and either vector cDNA or three truncation mutants of TCTP
(Met1-Gly69, Val70-Ala119, Glu120-Cys172) were co-transformed into
EGY48 yeast cells (Fig. 2C). Consistent with results from Fig. 2A and
B, cells containing p53 deletion mutant (Lys101-Pro300) with one
TCTP deletion mutant (Val70-Ala119) only grew on the deﬁcient
plates whereas the other deletion mutants (Met1-Gly69 and
Glu120-Cys172) failed to grow. Subsequent results on b-galactosi-
dase assay were also agreed with these results (Fig. 2C).
3.3. TCTP prevents p53 mediated apoptosis in lung carcinoma cells
As shown in Fig. S1 (Supplementary Fig. 1), the inhibition of
TCTP expression caused A549 cells to undergo instinctive and mas-
sive apoptosis and p53 overexpression is capable suppressing cell
proliferation by inducing apoptosis. To test whether TCTP and p53
show an additive effect or whether they antagonize each other in
regards to apoptosis, we measured the cell viability with A549 cellstransfected with Mock (expression vector only), p53 cDNA alone, or
TCTP cDNA alone, or co-transfected with p53 and TCTP, or co-trans-
fected p53 and siTCTP cDNAs (see detailed Materials and methods
in Supplementary data). As expected, nearly 55% of the cells died
after transfection of p53 cDNA alone when compared to mock
transfectant, whereas no change of cell viabilitywas observedwhen
transfected with TCTP cDNA alone (Fig. 3A). Interestingly, most of
cell viability was recovered when co-transfected with TCTP and
p53 cDNAs (Fig. 3A). This may indicate that TCTP antagonizes p53
mediated apoptosis of A549 cells. To conﬁrm this result, we inhib-
ited TCTP expressionwith siRNAwhenwe transfected p53 cDNA. As
shown in Fig. 3A, viability of p53 and siTCTP (siRNA of TCTP) trans-
fectant is markedly decreased when compared with p53 and TCTP
co-transfectant. Result showed that cell viability of co-transfectant
with siTCTP and p53 (2 lg) was relatively lower than that of 2 lg of
p53 cDNA alone. To verify that the reduction in cell numbers repre-
sented apoptosis, we employed 4,60-diamidino-2-phenylindole
(DAPI) staining to conﬁrm that the observed loss of proliferation
in A549 cells overexpressing mock, TCTP, siTCTP, p53, or sip53, or
co-transfected with TCTP and p53 cDNAs, co-transfected with p53
and siTCTP, or co-transfected siTCTP and sip53, or triple-transfected
with TCTP, siTCTP and p53 (see detailed Materials and methods in
Supplementary data). As expected, after transfection of p53 cDNA
alone compared to the mock transfectant, nearly 53% of cells
showed fragmented nuclei, whereas no change of cell viability
was observed when transfected with mock and TCTP cDNA alone.
Cells with a combination of p53 and TCTP demonstrated a signiﬁ-
cantly reduced number of cells containing fragmented DNA, but
those with TCTP-siRNA did not (Fig. 3B).
To deﬁne the mechanism of the functional relationship between
TCTP and p53-mediated apoptosis, we measured the caspase-3
Fig. 3. TCTP inhibits p53-induced apoptosis in lung carcinoma cells. Cell viability assay (A), DAPI staining (B), and caspase-3 activity assay (C) were performed using lung
carcinoma cells (A549 cells) transfected with each indicated cDNA construct. Mock means a transfectant with expression vector only (without insert). (A) Relative rates of cell
proliferation were determined by MTT assay. Amounts of MTT-formazan were determined by measuring absorbance at 540 nm, and sample absorbances were converted to
relative proliferation rates. Data are presented as means ± SEM. (B) Cells were stained with DAPI to visualize DNA fragmentations for assaying apoptosis. Arrows indicate
observed DNA fragmentations. (C) Caspase-3 activity was measured using a Spectramax 340 microplate reader in ﬂuorescence mode 400 nm (excitation) and 505 nm
(emission) according to the manufacturer’s protocol.
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in Supplementary data). Although TCTP is involved in cell prolifer-
ation, no signiﬁcant changes in caspase-3 activity were observed in
the transfectants of TCTP cDNA alone when compared to mock.
However, a signiﬁcant upregulation of caspase-3 activity was ob-
served in cells transfected with p53 cDNA alone versus the Mock
transfected cells. Strikingly, TCTP plus p53 overexpressed cells re-
stored caspase-3 activity almost similarly to those of Mock and
TCTP transfected cells (Fig. 3C). These results clearly showed thatTCTP inhibits p53 mediated apoptosis in human lung carcinoma
cells.
3.4. TCTP inhibits p53-mediated cell death via the destabilization of
p53
To deﬁne the mechanism by which TCTP inhibits p53 mediated
cell death, we assessed the stability of the p53 protein in the pres-
ence or absence of TCTP in A549 cells. In brief, mock and siTCTP
Fig. 4. TCTP decreases the half life of p53 protein. (A) siTCTP or Mock transfectants
were treated with cycloheximide for various times as indicated before total cell
lysates were prepared. Levels of p53, other Bcl-2 family members, TCTP and tubulin
(served as a protein loading control) in the cell lysates were then analyzed by
western blot with speciﬁc antibodies as indicated. (B) A549 cells were co-
transfected p53 cDNA with the each pEGFP-TCTP mutant (Met1-Gly69,
Val70-Ala119, Glu120-Cys172). The cells were treated with cycloheximide. Fourty
minutes after cycloheximide treatment, the whole cell lysates were prepared and
analyzed by western blot with speciﬁc antibodies p53, TCTP or b-actin to measure
the amounts of p53 protein remaining at the respective times. (C) A549 cells were
transfected with Mock or p53, or co-transfected p53 cDNA with the each pEGFP-
TCTP mutant (Met1-Gly69, Val70-Ala119, Glu120-Cys172). Three days after transfection,
the cells were stained with trypan blue and quantitated to analyze cell viability.
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lysates were harvested at 0, 20, and 40 min after treatment, and
immunoblotted with anti-p53 or anti-TCTP antibody. As shown
in Fig. 4A, the level of p53 protein evidenced a signiﬁcant reduction
in a time-dependent manner in the presence of TCTP. Conversely,
the level of p53 protein revealed slightly decrease for over
40 min in the absence of TCTP. In contrast, the protein levels of
two other TCTP non-interacting Bcl-2 family proteins (Bcl-2 and
BAX), and a-tubulin remained rather constant both in the control
and the TCTP knockdown lines. Taken together, this result indi-
cated that the instability of p53 is indeed speciﬁcally inﬂuenced
by the cellular levels of TCTP via the physiologically interactions
between TCTP and p53. This result was further supported by the
protein level of p53 is much increased in siTCTP transfectant than
that of mock transfectant (Fig. S2; Supplementary Fig. 2). Thus,
TCTP may inﬂuence on the half life of p53 protein or stability of
p53 protein. To conﬁrm this results, we co-transfected p53 cDNA
with the each TCTP mutant (Met1-Gly69, Val70-Ala119, Glu120-Cys172) and performed p53 stabilization assay and cell viability test
using these co-transfectants. For p53 stabilization assay, we har-
vested cell lysates at 40 min after cycloheximide treatment, and
immunoblotted with anti-p53 or anti-TCTP antibody. As shown
in Fig. 4B, the level of p53 protein was signiﬁcant decreased in
co-transfectant containing p53 and one deletion TCTP mutant
(Val70-Ala119). Also, cell viability in co-transfectant containing
p53 and one deletion TCTP mutant (Val70-Ala119) was recovered,
compared to transfectant containing p53 cDNA alone (Fig. 4C).
However, neither the level of p53 protein nor cell viability was
changed in co-transfectants containing p53 and the other deletion
mutant (Met1-Gly69 and Glu120-Cys172). These results clearly
showed that the interaction between p53 and TCTP accelerates
the destabilization of p53 in human lung carcinoma cells.4. Discussion
The ﬁrst molecular function of TCTP to be described was a
growth-related protein, and the importance of the biological
functions of TCTP have been extended to include cellular protein
interaction, regulation of cell cycle, and protein stabilization in
cancer [21,22]. In addition, Chen et al., [23] demonstrated that
homozygous mutants (TCTP/) and control mouse embryonic
ﬁbroblasts manifested similar proliferation activities to various
death stimuli. However, the underlying anti-apoptotic mechanisms
of mediated by TCTP still remain largely unknown.
To deﬁne the detailed functional role of TCTP during apoptosis,
we used yeast two-hybrid screening to identify novel TCTP-inter-
acting proteins. Tumor suppressor protein p53, whose interactions
were conﬁrmed, was one of the interacting proteins found through
a variety approaches. Furthermore, we provide genetic and bio-
chemical data to reveal that TCTP may regulate p53 activity by
affecting p53 protein stability. We also test whether TCTP regulate
p53 transcriptional activity. Result indicated that TCTP does not in-
hibit p53 transcriptional activity as shown in Fig. S3 (Supplemen-
tary Fig. 3).
To test whether TCTP expression affects p53-mediated apopto-
sis in response to DNA damaging agents, we irradiated both siTCTP
transfectant and mock transfectant with UV and measured the
expression pattern of p53 protein. As shown in Fig. S4 (Supplemen-
tary Fig. 4), TCTP expression affects p53 protein level in both unir-
radiated and UV irradiated conditions. Thus, we believed that TCTP
expression affects p53-mediated apoptosis in response to DNA
damaging agents.
Protein stability is regulated, in normal as well as malignant
cells, by ubiquitin-dependent proteolysis [17]. In addition, p53 is
reported primarily at the level of protein stability by its interacting
partner, Mdm2. Mdm2-deﬁcient mice die during early embryogen-
esis [18]. This early lethal phenotype can be suppressed completely
by simultaneous inactivation of p53, suggesting that the main
function of Hdm2 in vivo is to regulate p53 [19]. Also, previous
studies have shown that p53 stability can be regulated by various
post-translational modiﬁcations such as acetylation and phosphor-
ylation [24,25].
In this study, we showed evidence that the interaction between
p53 and TCTP accelerates the destabilization of p53 in human lung
carcinoma cells. The destabilization of one pro-apoptotic protein
by another anti-apoptotic protein has not been reported in litera-
ture and calls for further investigation. Also, these results may indi-
cate that a dynamic equilibrium between pools of p53 and p53
interacting protein such as TCTP regulate apoptotic homeostasis.
Further detailed characterizations of the gene expression pattern
and biochemical function of the TCTP in human malignancies
may provide us with a better understanding of the precise mecha-
nism that underlies lung tumorigenesis.
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